股本结构
单位：万股
| 公告日期 | 2025-07-29 | 2025-03-28 | 2024-12-10 | 2024-12-10 | 2024-10-24 | 2024-09-16 |
|---|---|---|---|---|---|---|
| 证券总股本 | 4615.41 | 4576.51 | 3106.23 | 3028.81 | 2883.23 | 2791.56 |
| 普通股本 | 4615.41 | 4576.51 | 3106.23 | 3028.81 | 2883.23 | 2791.56 |
| 优先股 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2025-04-30 | 2025-01-31 | 2024-12-09 | 2024-10-31 | 2024-10-14 | 2024-09-13 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2025-07-29 | 4615.41 | 未披露 |
更多>>
From April 30, 2024 to April 30, 2025
Shares issued pursuant to conversion of convertible debentures
Shares issued pursuant to ATM
|
2025-04-30 |
| 2025-03-28 | 4576.51 | 未披露 | 定期报告 | 2025-01-31 |
| 2024-12-10 | 3106.23 | 未披露 | 定期报告 | 2024-12-09 |
| 2024-12-10 | 3028.81 | 未披露 |
更多>>
From July 31, 2024 to October 31, 2024
Shares issued pursuant to conversion of convertible debentures
Shares issued pursuant to ATM
|
2024-10-31 |
| 2024-10-24 | 2883.23 | 未披露 | 定期报告 | 2024-10-14 |
| 2024-09-16 | 2791.56 | 未披露 | 定期报告 | 2024-09-13 |
| 2024-07-29 | 2730.23 | 未披露 | 定期报告 | 2024-07-24 |
| 2024-07-29 | 2694.45 | 未披露 |
更多>>
From April 30, 2023 to April 30, 2024
Shares issued pursuant to issuance of common shares
|
2024-04-30 |
| 2023-12-14 | 2631.53 | 未披露 | 定期报告 | 2023-12-14 |
| 2023-12-07 | 2615.03 | 未披露 |
更多>>
Common stock offered 1,100,000 shares by the company
|
2023-12-08 |
| 2023-07-10 | 2505.03 | 未披露 |
更多>>
From April 30, 2022 to April 30, 2023
Shares issued pursuant to option exercise
Shares issued pursuant to conversion of convertible debentures
|
2023-04-30 |
| 2022-11-17 | 2493.54 | 未披露 | 定期报告 | 2022-11-11 |
| 2022-07-29 | 2483.67 | 未披露 | 定期报告 | 2022-07-29 |
| 2022-07-29 | 2447.68 | 未披露 |
更多>>
From April 30, 2021 to April 30, 2022
Shares issued pursuant to deferred acquisition payment to IPA Europe
Shares issued pursuant to option exercise
Shares issued pursuant to warrant exercise
Shares issued pursuant to conversion of convertible debentures
Shares issued pursuant to acquisition of BioStrand
|
2022-04-30 |
| 2022-04-14 | 2353.90 | 未披露 | 定期报告 | 2022-04-14 |
| 2022-03-16 | 1946.12 | 未披露 | 定期报告 | 2022-03-16 |
| 2021-12-13 | 1942.97 | 未披露 | 定期报告 | 2021-12-10 |
| 2021-11-12 | 1937.47 | 未披露 | 定期报告 | 2021-10-29 |
| 2021-09-09 | 1934.72 | 未披露 | 定期报告 | 2021-09-08 |
| 2021-09-09 | 1926.93 | 未披露 |
更多>>
From April 30, 2021 to July 31, 2021
Shares issued pursuant to deferred acquisition payment to IPA Europe
Shares issued pursuant to option exercise
Shares issued pursuant to warrant exercise
Shares issued pursuant to conversion of convertible debentures
|
2021-07-31 |
| 2021-07-28 | 1923.30 | 未披露 | 定期报告 | 2021-07-27 |
| 2021-07-28 | 1916.92 | 未披露 |
更多>>
From April 30, 2020 to April 30, 2021
Shares issued pursuant to deferred acquisition payment to IPA Europe
Shares issued pursuant to deferred acquisition payment to UPE
Shares issued pursuant to option exercise
Shares issued pursuant to warrant exercise
Shares issued pursuant to conversion of convertible debentures
Shares issued pursuant to bought deal offering of common shares
|
2021-04-30 |
| 2021-03-18 | 1907.90 | 未披露 | 定期报告 | 2021-03-17 |
| 2021-02-11 | 1897.80 | 未披露 |
更多>>
1.IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA / TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, today announced that the over-allotment option (the “Option”) granted in connection with its previously announced bought deal offering of 1,616,293 common shares (the “Common Shares”) in the capital of the Company (the “Offering”), has been fully exercised. H.C. Wainwright & Co. has purchased additional 242,443 shares of the Company (the “Additional Shares”) at the public offering price of $13.45 per Additional Share for additional aggregate gross proceeds to the Company of approximately $3.3 million, less underwriting discounts and commissions.
|
2021-02-10 |
| 2021-02-08 | 1873.55 | 未披露 |
更多>>
1.Securities Offered: Treasury offering of 1,616,293 Common Shares.
|
2021-02-08 |
| 2021-03-18 | 1711.92 | 未披露 |
更多>>
From April 30, 2020 to January 29, 2021
Shares issued pursuant to deferred acquisition payment to IPA Europe
Shares issued pursuant to deferred acquisition payment to UPE
Shares issued pursuant to option exercise
Shares issued pursuant to warrant exercise
Shares issued pursuant to conversion of convertible debentures
|
2021-01-29 |
| 2021-01-05 | 1676.18 | 未披露 | 定期报告 | 2021-01-05 |
| 2020-12-22 | 1680.86 | 未披露 | 定期报告 | 2020-12-30 |
From April 30, 2024 to April 30, 2025
Shares issued pursuant to conversion of convertible debentures
Shares issued pursuant to ATM
From July 31, 2024 to October 31, 2024
Shares issued pursuant to conversion of convertible debentures
Shares issued pursuant to ATM
From April 30, 2023 to April 30, 2024
Shares issued pursuant to issuance of common shares
Common stock offered 1,100,000 shares by the company
From April 30, 2022 to April 30, 2023
Shares issued pursuant to option exercise
Shares issued pursuant to conversion of convertible debentures
From April 30, 2021 to April 30, 2022
Shares issued pursuant to deferred acquisition payment to IPA Europe
Shares issued pursuant to option exercise
Shares issued pursuant to warrant exercise
Shares issued pursuant to conversion of convertible debentures
Shares issued pursuant to acquisition of BioStrand
From April 30, 2021 to July 31, 2021
Shares issued pursuant to deferred acquisition payment to IPA Europe
Shares issued pursuant to option exercise
Shares issued pursuant to warrant exercise
Shares issued pursuant to conversion of convertible debentures
From April 30, 2020 to April 30, 2021
Shares issued pursuant to deferred acquisition payment to IPA Europe
Shares issued pursuant to deferred acquisition payment to UPE
Shares issued pursuant to option exercise
Shares issued pursuant to warrant exercise
Shares issued pursuant to conversion of convertible debentures
Shares issued pursuant to bought deal offering of common shares
1.IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA / TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, today announced that the over-allotment option (the “Option”) granted in connection with its previously announced bought deal offering of 1,616,293 common shares (the “Common Shares”) in the capital of the Company (the “Offering”), has been fully exercised. H.C. Wainwright & Co. has purchased additional 242,443 shares of the Company (the “Additional Shares”) at the public offering price of $13.45 per Additional Share for additional aggregate gross proceeds to the Company of approximately $3.3 million, less underwriting discounts and commissions.
1.Securities Offered: Treasury offering of 1,616,293 Common Shares.
From April 30, 2020 to January 29, 2021
Shares issued pursuant to deferred acquisition payment to IPA Europe
Shares issued pursuant to deferred acquisition payment to UPE
Shares issued pursuant to option exercise
Shares issued pursuant to warrant exercise
Shares issued pursuant to conversion of convertible debentures